InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,462.54
(
-0.04%
)
US TECH 100
19,052.00
(
-0.81%
)
Dow Jones
39,423.46
(
0.70%
)
Brent Oil
85.28
(
1.49%
)
Bitcoin
59,969.59
(
-5.04%
)
Post# of 252331
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119907
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 97508

Wednesday, 10/27/2010 4:22:41 AM

Wednesday, October 27, 2010 4:22:41 AM

Post# of 252331
BMY has begun a rolling submission for Apixaban based on the AVERROES (non-warfarin) study and expects to complete the submission in 1Q11. It appears that we were wrong when we presumed that BMY would wait for the results of the ARISTOTLE study before filing an NDA.

BMY’s plan to submit a “freestanding” NDA based on AVERROES makes a lot of sense, actually. Management thinks the non-warfarin part of the AF market is where Apixaban can be strongly differentiated from Pradaxa and Xarelto insofar as those drugs will not have data from head-to-head trials vs aspirin. (Source: BMY’s 3Q10 CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up